Precision Business Insights
Portfolio

0
  • No products in the cart.
Total:$ 0.00
 

Research Reports

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Awaiting product image


 




	

		

			
Request Methodology  Request Sample


		
 
	
 
	

		

			
		
 
	
 
		

			

				
				

																		

						

							

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 


Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment


 


Overview:


Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.


ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.


 


Segmentation:


By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:


    

  • Interferon Beta-1a
    • 

  • Imatinib
    • 

  • Sivelestat
    • 

  • L-Citrulline
    • 

  • Poractantalfa
    • 

  • Ganciclovir
    • 

  • Others
    • 



By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:


    

  • Oral
    • 

  • Parenteral
    • 



By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:


    

  • Preclinical Trials
    • 

  • Phase 1
    • 

  • Phase 2
    • 

  • Phase 3
    • 

  • Phase 4
    • 



By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:


    

  • AltorBioScience
    • 

  • Genentech, Inc.
    • 

  • Faron Pharmaceuticals Ltd.
    • 

  • AltorBioScience
    • 

  • Suntory Pharmaceutical
    • 

  • Eli Lilly and Company
    • 

  • Asklepion Pharmaceuticals, LLC
    • 

  • BioMarck Pharmaceuticals, Ltd.
    • 

  • Others
    • 



 


Space Analysis:


    

  • In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
    • 

  • In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)
    • 



 


Report Description:


Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


 


Key Features of the Report:


    

  • Provides the information related to universities and research institutes working in the therapeutics development
    • 

  • Report comprehensively covers the all active and discontinued studies
    • 

  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
    • 

  • Presents the prominent targets for drug development in each stage of clinical trial
    • 

  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases
    • 



 

						

					

														

						

							
    

  • AltorBioScience
    • 

  • Genentech, Inc.
    • 

  • Faron Pharmaceuticals Ltd.
    • 

  • AltorBioScience
    • 

  • Suntory Pharmaceutical
    • 

  • Eli Lilly and Company
    • 

  • Asklepion Pharmaceuticals, LLC
    • 

  • BioMarck Pharmaceuticals, Ltd.
    • 


						

					

														

						

							
1. Executive Summary


 


2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Introduction


 


2.1. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Taxonomy


2.2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market –Definitions


2.2.1. Drugs


2.2.2. Route of Administration


2.2.3. Trial Phase


 


3. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics


 


3.1. Drivers


3.2. Restraints


3.3. Opportunities/Unmet Needs of the Market


3.4. Trends


3.5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis


3.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Competition Landscape


3.7. Epidemiology


 


4. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024


 


4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)


4.3. Market opportunity analysis


 


5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market, By Drugs, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


5.1. Interferon Beta-1a


5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.1.3. Market Opportunity Analysis


 


5.2. Imatinib


5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.2.3. Market Opportunity Analysis


 


5.3. Sivelestat


5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.3.3. Market Opportunity Analysis


 


5.4. L-Citrulline


5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.4.3. Market Opportunity Analysis


 


5.5. Poractantalfa


5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.5.3. Market Opportunity Analysis


 


5.6. Ganciclovir


5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.6.3. Market Opportunity Analysis


 


5.7. Others


5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


5.7.3. Market Opportunity Analysis


 


6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration,2013 – 2017 and Forecast, 2017 – 2024


 


6.1.  Oral


6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


6.1.3. Market Opportunity Analysis


 


6.2. Parenteral


6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


6.2.3. Market Opportunity Analysis


 


7. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


7.1. Preclinical Trials


7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


7.1.3. Market Opportunity Analysis


7.2. Phase 1


7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


7.2.3. Market Opportunity Analysis


 


7.3. Phase 2


7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


7.3.3. Market Opportunity Analysis


 


7.4. Phase 3


7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


7.4.3. Market Opportunity Analysis


 


7.5. Phase 4


7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


7.5.3. Market Opportunity Analysis


 


8. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


8.1. North America


8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


8.1.3. Market Opportunity Analysis


 


8.2. Europe


8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


8.2.3. Market Opportunity Analysis


 


8.3. Asia-Pacific


8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


8.3.3. Market Opportunity Analysis


 


8.4. Latin America


8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


8.4.3. Market Opportunity Analysis


 


8.5. Middle East and Africa


8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)


8.5.3. Market Opportunity Analysis


 


8.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


 


9. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


9.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)


9.1.1. Interferon Beta-1a


9.1.2. Imatinib


9.1.3. Sivelestat


9.1.4. L-Citrulline


9.1.5. Poractantalfa


9.1.6. Ganciclovir


9.1.7. Others


 


9.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


9.2.1. Oral


9.2.2. Parenteral


 


9.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


9.3.1. Preclinical Trials


9.3.2. Phase 1


9.3.3. Phase 2


9.3.4. Phase 3


9.3.5. Phase 4


 


9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)


9.4.1. U.S.


9.4.2. Canada


 


9.5. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


9.6. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends


 


10. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


10.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)


10.1.1. Interferon Beta-1a


10.1.2. Imatinib


10.1.3. Sivelestat


10.1.4. L-Citrulline


10.1.5. Poractantalfa


10.1.6. Ganciclovir


10.1.7. Others


 


10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


10.2.1. Oral


10.2.2. Parenteral


 


10.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


10.3.1. Preclinical Trials


10.3.2. Phase 1


10.3.3. Phase 2


10.3.4. Phase 3


10.3.5. Phase 4


 


10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)


10.4.1. Germany


10.4.2. UK


10.4.3. France


10.4.4. Spain


10.4.5. Italy


10.4.6. Russia


10.4.7. Poland


10.4.8. Rest of Europe


 


10.5. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


10.6. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends


 


11. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


11.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)


11.1.1. Interferon Beta-1a


11.1.2. Imatinib


11.1.3. Sivelestat


11.1.4. L-Citrulline


11.1.5. Poractantalfa


11.1.6. Ganciclovir


11.1.7. Others


 


11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


11.2.1. Oral


11.2.2. Parenteral


 


11.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


11.3.1. Preclinical Trials


11.3.2. Phase 1


11.3.3. Phase 2


11.3.4. Phase 3


11.3.5. Phase 4


 


11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       


11.4.1. Japan


11.4.2. China


11.4.3. India


11.4.4. ASEAN


11.4.5. Australia & New Zealand


11.4.6. Rest of Asia-Pacific


 


11.5. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


11.6. Asia-PacificAcute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends


 


12. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


12.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)


12.1.1. Interferon Beta-1a


12.1.2. Imatinib


12.1.3. Sivelestat


12.1.4. L-Citrulline


12.1.5. Poractantalfa


12.1.6. Ganciclovir


12.1.7. Others


 


12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


12.2.1. Oral


12.2.2. Parenteral


 


12.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


12.3.1. Preclinical Trials


12.3.2. Phase 1


12.3.3. Phase 2


12.3.4. Phase 3


12.3.5. Phase 4


 


12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)


12.4.1. Brazil


12.4.2. Mexico


12.4.3. Argentina


12.4.4. Venezuela


12.4.5. Rest of Latin America


 


12.5. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


12.6. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends


 


13. Middle East and Africa Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)


 


13.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)


13.1.1. Interferon Beta-1a


13.1.2. Imatinib


13.1.3. Sivelestat


13.1.4. L-Citrulline


13.1.5. Poractantalfa


13.1.6. Ganciclovir


13.1.7. Others


 


13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


13.2.1. Oral


13.2.2. Parenteral


 


13.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)


13.3.1. Preclinical Trials


13.3.2. Phase 1


13.3.3. Phase 2


13.3.4. Phase 3


13.3.5. Phase 4


 


13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)


13.4.1. Gulf Cooperation Council (GCC) Countries


13.4.2. Israel


13.4.3. South Africa


13.4.4. Rest of MEA


 


13.5. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024


13.6. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends


 


14. Competition Landscape


 


14.1. Strategic Dashboard of Top Market Players


14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)


14.2.1. AltorBioScience


14.2.2. Genentech, Inc.


14.2.3. Faron Pharmaceuticals Ltd.


14.2.4. AltorBioScience


14.2.5. Suntory Pharmaceutical


14.2.6. Eli Lilly and Company


14.2.7. Asklepion Pharmaceuticals, LLC


14.2.8. BioMarck Pharmaceuticals, Ltd.


14.2.9. Others


 


15. Research Methodology


16. Key Assumptions and Acronyms

						

					

														

						

							
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements




 

						

					

														

						

													

					

								

			

		 

		
	

		

			

		
 
	
 

	

		

			
		
 
	
 


	




        

            

    
		
	






	
		





	




		

Contact SalesTOLL FREE: +1-866-598-1553